CRM1 Antibody - #DF13364

Fig. 1. The expression and prognostic analysis of XPO1 gene in HCC. (A) and (B) Bioinformatics analysis was used to explore the expression of the XPO1 gene by using the GEO data (GSE36376, A) and TCGA-HCC (B) dataset. Data in (A) and (B) were analyzed by the Wilcox test. (C) The curve of risk score. More patient mortality corresponded to a higher risk score. (D) Kaplan-Meier survival analysis. (E) Immunohistochemical detection of XPO1 protein expression in para-carcinoma and carcinoma of HCC samples. bar= 100 µm. (F) XPO1 protein expression level was detected by Immunohistochemistry. Comparing the expression of XPO1 protein in carcinoma and para-carcinoma tissues in HCC. Data statistics using the χ2 test. P: Para-carcinoma; T: Carcinoma. * P 

Fig. 2. XPO1 promotes HCC progression and sorafenib resistance. (A) The expression of XPO1 in normal hepatocytes (HepaRG) and HCC cell lines (Hep3B, HepG2 and Huh7) by western Blotting. n = 3. (B) We used Western blot to verify the overexpression of XPO1. n = 3. (C) A soft agar colony formation assay was performed to evaluate the clonogenicity of HepG2/XPO1 KD cells. n = 3. (D) Transwell assay of XPO1 KD cells. bar= 20 µm. n = 3. (E) HepG2/XPO1 KD and HepG2/Vector cells were transplanted on nude mice, and tumor weight was measured. n = 3. (F) R analysis of the correlation between XPO1 and tumor proliferation signature in TCGA HCC dataset. (G) R analysis of XPO1 mRNA expression level using GEO dataset. (H) The IC50 values of Huh7 and Huh7/SR cells treated with sorafenib. n = 6. (I) Cells were transfected with mRFP-GFP-LC3 plasmid. Observation of autophagy by fluorescence microscope. bar= 5 µm. n = 3. (J) Detection of apoptosis level by Tunel assay. n = 3. (K) The IC50 values of Huh7/SR XPO1 KD and Huh7/SR Vector cells treated with sorafenib. n = 6.